Angelo Gordon & Co’s Protalix BioTherapeutics PLX Stock Holding History

Angelo Gordon & Co’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-105,707	Closed	-$470K	–	75
2016 Q4	$470K	Buy	+105,707	New	+$472K	0.03%	64

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Angelo Gordon & Co's PLX Position: Q1 2017 in Review

Angelo Gordon & Co sold out of Protalix BioTherapeutics (PLX) in Q1 2017, closing a stake of 105,707 shares — an estimated $470K sold.

Angelo Gordon & Co first reported a position in PLX in Q4 2016 and held it in 1 quarter. The position peaked at $470K in Q4 2016. 28 funds tracked by Wall St. Rank hold PLX as of Q1 2017.

Angelo Gordon & Co reported no remaining Protalix BioTherapeutics position as of Q1 2017 after selling out during the quarter.
Angelo Gordon & Co sold 105,707 Protalix BioTherapeutics shares in Q1 2017, an estimated $470K.
Angelo Gordon & Co first reported a position in Protalix BioTherapeutics in Q4 2016 and held it in 1 quarter.
Angelo Gordon & Co's Protalix BioTherapeutics position peaked at $470K in Q4 2016.
28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2017.

Based on Angelo Gordon & Co's 13F filing for Q1 2017, filed 12 May 2017.